BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Colorcon
Healthtrust
Fish and Richardson
Novartis
Federal Trade Commission
Teva
Express Scripts
Medtronic

Generated: January 17, 2018

DrugPatentWatch Database Preview

Recro Gainesville Company Profile

« Back to Dashboard

What is the competitive landscape for RECRO GAINESVILLE, and what generic and branded alternatives to RECRO GAINESVILLE drugs are available?

RECRO GAINESVILLE has two approved drugs.



Summary for Recro Gainesville
US Patents:0
Tradenames:2
Ingredients:1
NDAs:2

Drugs and US Patents for Recro Gainesville

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-001 May 29, 1990 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-003 Nov 25, 1998 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-004 May 10, 1996 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-003 Jan 9, 1992 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-001 Nov 25, 1998 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-002 Nov 25, 1998 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-002 May 29, 1990 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Recro Gainesville

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-001 Nov 25, 1998 ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-001 May 29, 1990 ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-003 Jan 9, 1992 ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-002 Nov 25, 1998 ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-004 May 10, 1996 ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-002 May 29, 1990 ➤ Subscribe ➤ Subscribe
Recro Gainesville VERELAN PM verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020943-003 Nov 25, 1998 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for RECRO GAINESVILLE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 100 mg and 200 mg ➤ Subscribe 7/20/2006
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 5/19/2006
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Colorcon
Cantor Fitzgerald
Express Scripts
Teva
Fish and Richardson
Medtronic
US Army
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot